Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA-DR3-restricted CD4+ T cells specific for arrestin peptide 291–310 represent a specialized population of autoreactive helper T lymphocytes that play a critical role in the pathogenesis of autoimmune uveitis (de Smet et al., 1990). These cells possess T-cell receptors (TCRs) that specifically recognize the 291–310 amino acid sequence of S-arrestin (also known as S-antigen), a protein primarily located in retinal photoreceptor cells, when presented by the HLA-DR3 (HLA-DRB1*03:01) MHC class II molecule (Wildner & Diedrichs-Möhring, 2003). Upon activation, these autoreactive T cells infiltrate the eye and secrete pro-inflammatory cytokines such as interferon-gamma and IL-17, orchestrating an inflammatory response that leads to retinal tissue destruction and vision loss (Caspi, 2010). In therapeutic contexts, these cells are targeted for modulation to restore immune tolerance, often through broad-spectrum immunosuppressants like cyclosporine or experimental antigen-specific tolerization strategies. Monitoring the frequency and activation state of this specific T-cell population serves as a potential biomarker for disease activity and treatment efficacy in ocular inflammatory conditions.
Inhibition of T-cell receptor signaling, suppression of T-cell proliferation, and reduction of pro-inflammatory cytokine secretion.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA-DR3-restricted arrestin-specific CD4+ T cell.